Epistem will exhibit at the 61st Annual Society of Toxicology (SOT) Meeting
Epistem will be exhibiting at the 61st Annual SOT Meeting and ToxExpo in San Diego, 27-31 March.
Epistem to exhibit at the American Association for Cancer Research (AACR) Annual Meeting 2022
Epistem is looking forward to exhibiting at the first in-person AACR conference in two years (April 8-13, 2022, New Orleans, LA).
Epistem receives ISO15189 accreditation
Epistem receives ISO15189:2012 accreditation validating its #COVID19 testing and provides further evidence of the quality to which we operate, having also been GCLP accredited for over 10 years. It also confirms that the tests we perform are carried out to the highest industry standards.
Epistem licence Hubrecht Organoid Technology to expand preclinical toxicology service portfolio
Epistem Limited has announced the expansion of its in vitro model portfolio by the completion of an agreement with Hubrecht Organoid Technology (HUB) to enable the delivery of an increased range of multi species organoid models. Services are focused on the identification of off target or off tissue intestinal toxicities associated with various therapeutics.
Epistem completes board line up and launches new NGS service
Epistem Limited, the Manchester based pre-clinical and clinical research services company announces the completion of its Board appointments. Investment from the Foresight group in June 2018 enabled expansion of the research services, the first of which is launched in December 2018 - GCLP compliant Next Generation Sequencing (NGS) services.